Review of Intralesional Collagenase Clostridium Histolyticum Injection Therapy and Related Combination Therapies in the Treatment of Peyronie's Disease (an Update)
| Autor: | Ayad Yousif, Wayne J.G. Hellstrom, Caleb Natale, David M. McLellan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
endocrine system medicine.medical_specialty Sildenafil Urology Endocrinology Diabetes and Metabolism Penile Induration 030232 urology & nephrology Injections Intralesional 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Collagenase clostridium histolyticum medicine Humans Adverse effect 030219 obstetrics & reproductive medicine Collagenase Clostridium histolyticum Injection business.industry Obstetrics and Gynecology medicine.disease Nonsurgical treatment Psychiatry and Mental health Microbial Collagenase Treatment Outcome Reproductive Medicine chemistry Standard protocol Penile curvature Peyronie's disease business Penis medicine.drug |
| Zdroj: | Sexual Medicine Reviews. 9:340-349 |
| ISSN: | 2050-0521 |
| DOI: | 10.1016/j.sxmr.2020.01.005 |
| Popis: | Introduction Collagenase Clostridium histolyticum (CCH) is an injectable agent used to treat Peyronie's disease (PD) by enzymatically degrading the interstitial collagen in plaques. CCH has been administered via multiple treatment protocols, in combination therapies, to patients with varying curvatures and in both the acute and stable phases of this condition. Objectives To review the current literature and provide an update on CCH as an injectable therapy for PD, as a singular therapy or in conjunction with combination therapies, and its associated complications. We provide a brief background of PD treatments, evaluate CCH efficacy in penile curvature reduction and subjective improvement in a variety of protocols, and compare combination therapies (penile traction, sildenafil), plaque location, and efficacy in both acute and stable diseases. Methods We performed a systematic review of the existing PubMed literature pertaining to CCH injection therapy in the treatment of PD and compared the effectiveness to different treatment modalities. Results CCH is a safe and effective injectable agent for all curvature directions in both acute and stable PD. It can be used in conjunction with multiple penile modeling techniques, in combination with sildenafil, and following a shortened administration protocol. Moderate to severe treatment-related adverse events occur at a rate of 9% and are typically managed conservatively. Conclusion Intralesional injections of CCH are FDA approved as a nonsurgical treatment for men with PD. The IMPRESS trials were instrumental in demonstrating the efficacy and safety of CCH and provided a standard protocol for administration. Additional studies are required to optimize treatment protocols and use in combination therapies. Further investigation of patients with ventral curvatures, hourglass deformities, and those in acute phase is needed. Natale C, McLellan D, Yousif A, et al. Review of Intralesional Collagenase Clostridium Histolyticum Injection Therapy and Related Combination Therapies in the Treatment of Peyronie's Disease (an Update). Sex Med 2021;9:340–349. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|